[ ]

under 37 CFR 1.97(i):

(Filed after payment of issue fee)

	PATENT APPLICAT
	DOCKET NO.: 2825-202
•	1///

	IN '	THE UNITED STATES PA	TENT AND TRADEM	ARK OFFICE OFF	
Applic	ants:	Todd R. Golub, Eric S. Lan	der, Scott Pomeroy and	d Pablo Tamayo	
Applic	ation No.:	10/066,305	Group Art Unit:	1642	
Filed:		January 31, 2002	Examiner:	K. Canella	
Confir	mation No.:	2026			
Title:		BRAIN TUMOR DIAGNO	SIS AND OUTCOME	PREDICTION	
	<u>\</u>	I hereby certify that this correspon States Postal Service with sufficient addressed to Assistant Commissione 22202  on 02/14/03  Date  Carol M	postage as First Class Mail in an are for Patents, P.O. Box 2327, Arling Francisco Signature  1. Bowerman  e of person signing certificate	Provelope ngton, VA	
Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202					
Sir:			02/21/2 01 FC:1	003 MMOHRMM1 00000091 10066305	
This In	nformation Dis	closure Statement is submitte	1	180.00 QP	
[]	under 37 CFR (First/Second submit	R 1.129(a), or ssion after Final Rejection)			
[ ]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).				
.[X]	under 37 CFR	1.97(c) together with either	:		
	[X] a State	ement under 37 CFR 1.97(e),	as checked below, or		
		0.00 fee under 37 CFR 1.17(p. 97(b) time period, but before final action of		occurs first)	
[ ]	under 37 CFR	1.97(d) together with:			
	[ ] a State	ement under 37 CFR 1.97(e),	as checked below, and	l	
	~ -	0.00 fee under 37 CFR 1.17(ption or notice of allowance, whichever occur	· ·	of the issue fee)	

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

## Statement Under 37 CFR 1.97(e)

[X]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or						
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
Stater	nent Un	der 37 (	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000				
[X]	comm was n	iunicatio ot receiv	nformation contained in the Information Disclosure Statement was cited in a n from a foreign patent office in a counterpart application and this communication ed by any individual designated in § 1.56(c) more than thirty days prior to the formation Disclosure Statement.				
[X]	Enclosed herewith is form PTO-1449:						
	[X]	Copies	es of the cited references are enclosed.				
	[ ]	Applic	s of cited references are enclosed except those entered in prior application, U.S. ation No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]				
	[X]	The list	sted references were cited in the enclosed International Search Report in a rpart foreign application.				
	[ ]	The "cunder	oncise explanation" requirement (non-English references) for reference(s) [ 37 CFR 1.98(a)(3) is satisfied by:				
		[ ]	the explanation provided on the attached sheet.				
		[ ]	the explanation provided in the Specification.				
•	1	[ ]	submission of the enclosed International Search Report.				
		[ ]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.				
		[ ]	the enclosed English language abstract.				

[ ]	Appli	cant requests that the following n	non-published pending applic	cations be considered:	
Examiner's Initials					
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]	
		Examiner	Date	_	
	r 7		1		
	[ ]	A copy of each above-cited app	_		
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [	nt claims, is enclosed, except ], to which priority under	
		r is requested to return a copy of ere considered with the next offic		plications indicating which	
It is re	questec	I that the information disclosed h	erein be made of record in the	nis application.	
Metho	d of pa	yment:			
[ ]		ck for the fee noted above is encloped apparent of this S		cluded in the check with the	
[ ]	Please	e charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is sed.			
[X]	Please	se charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.			
		F	Respectfully submitted,		
•	•	F	HAMILTON, BROOK, SMI	ΓΗ & REYNOLDS, P.C.	
		I F T	By	Téannie	

Concord, MA 01742-9133
Dated: 2/14/03

- T	6. T.						_	
PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 2825.2023-001	APPLICATION NO. 10/066,305			
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Todd R. Golub et al.					
		February 14, 2003		FILING DATE January 31, 2002	CONFIRMA'	TION NO.	GROUP	
	(Use	several sheets if nece	essary)	Danuary 51, 2002				
	10	E JC10	U.S.	PATENT DOCUMENTS	T · · · ·	An	<del></del>	
EXAM- INER INI- TIAL	) 0 %	DOCUMENT NU	MBER	ISSUE DATE / PUBLICATION DATE	CLASS CLASS YES NO			Ò
	A <sub>A</sub>	TEMI & TRADE			ECHC	~ 6 ~.	2003	
			FOREIG	N PATENT DOCUMENTS		ENTER 16	<u></u>	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	10/2000	ATION NO
	AL	WO 02/02799	10 JAN 02	PCT				
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinen	t Pages, .	Etc.)		
	AW2			terogeneity in Medullok Tumor Biology," J. Ch			4:411-	-417
-	AX2	Bertucci, F. et al., Gene expression profiling of primary breast carcinomas using arrays of candidate genes," Hum. Mol. Genet., 9:2981-2991 (2000).						
	AY2	Caskey, L. et al., "Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling," Histol. Histopathol., 15:971-981 (2000).						
	AZ2	Celis, J. et al., "Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics," FEBS Lett., 480:2-16 (2000).						
	AR3	Golub, T. et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring," Science, 286:531-537 (1999).						
	AS3	Huang, H. et al., "Gene Expression Profiling of Low-Grade Diffuse Astrocytes by cDNA Arrays," Cancer Res., 60:6868-6874 (2000).						
,	AT3	Liotta, L. and Petricoin, E., "Molecular Profiling of Human Cancer," Nat. Rev. Genet., 1:48-56 (2000).						
	AU3	Michiels, E. et al., "Genes differentially expressed in medulloblastoma and fetal brain," Physiol. Genomics, 1:83-91 (1999).						
	AV3	Ross, D. et al., Systematic variation in gene expression patterns in human cancer cell lines," Nat. Genet., 24:227-235 (2000).						
	AW3	Scherf, U. et al., "A gene expression database for the molecular pharmacology of cancer," Nat. Genet., 236-244 (2000).						
	AX3	Watson, M. et al., "Gene Expression Profiling with Oligonucleotide Microarrays Distinguishes World Health Organization Grade of Oligodendrogliomas," Cancer Res., 61:1825-1829 (2001).						
EXAMIN	IER			DATE CONSIDERED				